(Q46577596)

23 December 2017

title

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer (English)

1 reference

23 December 2017

main subject

phase II clinical trial

1 reference

1 reference

6

1 reference

23 December 2017

Joseph Fontana

object named as

Joseph Fontana

2

0 references

George Wilding

5

object named as

George Wilding

1 reference

23 December 2017

Eric J Small

1

1 reference

23 December 2017

Nizar Tannir

3

1 reference

23 December 2017

Robert S DiPaola

4

1 reference

23 December 2017

Renee Bailey Iacona

7

1 reference

23 December 2017

Fairooz F Kabbinavar

8

1 reference

23 December 2017

publication date

1 October 2007

1 reference

23 December 2017

published in

BJU International

1 reference

23 December 2017

volume

100

1 reference

23 December 2017

page(s)

765-769

1 reference

23 December 2017

issue

4

1 reference

23 December 2017

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07121.X

10.1111/J.1464-410X.2007.07121.X

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

17822457

1 reference

23 December 2017